Document Detail

Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.
MedLine Citation:
PMID:  23217529     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Treatment of venous thromboembolism (VTE) in long-term care (LTC) settings has received little empirical study.
OBJECTIVE: Among residents with VTE in nursing homes, this analysis evaluated frequency of anticoagulant use, the proportion of residents newly started on warfarin who persisted on therapy (≥3 months), and the association of key resident characteristics, including bleeding risk, with warfarin use and persistence.
METHODS: Using the AnalytiCare LTC database (US), eligible residents had deep vein thrombosis or pulmonary embolism coded in the Minimum Data Set (MDS) 2.0 during the uptake period April 1, 2007 through December 31, 2008 (earliest VTE was index date) and had 1 or more MDS assessment(s) over the 90-day preindex period, each negative for VTE. Logistic regression evaluated the association of resident characteristics with warfarin use. Cox regression evaluated persistence with warfarin therapy.
RESULTS: The median age of residents with VTE included in the analysis (N = 489) was 80 years; 73% received anticoagulant therapy and 66% were prescribed warfarin ±45 days of the index date. Multivariate logistic regression identified several factors significantly associated with warfarin use: location in South Central region (odds ratio [OR] = 1.94, P = 0.019) and the Western region (OR = 2.53, P = 0.005) [both vs reference South Atlantic]; body mass index categories normal (OR = 2.73, P = 0.045), overweight (OR = 4.21, P = 0.005), and obese (OR = 3.82, P = 0.010) (both vs reference underweight); Alzheimer's/dementia (OR = 0.52, P = 0.024); cancer (OR = 0.39, P = 0.008); and moderate-dependent versus independent physical functioning (OR = 2.59, P = 0.003). Of residents newly started on warfarin therapy with no history of cancer (n = 149), 28% discontinued warfarin within 90 days of initiation. Peripheral vascular disease (PVD) (OR = 4.07, P < 0.001), Alzheimer's disease/dementia (OR = 2.55, P = 0.046), and antipsychotic use (OR = 4.60, P < 0.001) were all significantly associated with discontinuation.
CONCLUSIONS: Patients in specific geographic regions who were underweight, had Alzheimer's disease/dementia or cancer, or had independent physical functioning were less likely to receive warfarin. Nonpersistence of warfarin therapy was strongly related to antipsychotic use, presence of dementia, or PVD.
Gregory Reardon; Naushira Pandya; Edith A Nutescu; Joyce Lamori; Chandrasekhar V Damaraju; Jeff Schein; Brahim K Bookhart
Related Documents :
23639269 - Successful treatment of mechanical mitral valve thrombosis without thrombolytic therapy...
24918369 - Microbiological changes after periodontal therapy in diabetic patients with inadequate ...
23378159 - Is abandonment of nonoperative management of hypertrophic pyloric stenosis warranted?
24042529 - Successful treatment of recurrent candidemia due to candidal thrombophlebitis associate...
24134539 - Cryoballoon versus rf ablation in paroxysmal atrial fibrillation: results from the germ...
25062719 - Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-u...
18634739 - The benefit of modified rehabilitation and minimally invasive techniques in total hip r...
22875309 - Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy i...
17383459 - Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of geriatric pharmacotherapy     Volume:  10     ISSN:  1876-7761     ISO Abbreviation:  Am J Geriatr Pharmacother     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101190325     Medline TA:  Am J Geriatr Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  361-72     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
Informagenics, LLC, Worthington, Ohio; The Ohio State University College of Pharmacy, Columbus, Ohio. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Complications related to therapeutic anticoagulation in total hip arthroplasty.
Next Document:  Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Net...